These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 15634780)
21. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Petroske E; Meredith GE; Callen S; Totterdell S; Lau YS Neuroscience; 2001; 106(3):589-601. PubMed ID: 11591459 [TBL] [Abstract][Full Text] [Related]
22. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577 [TBL] [Abstract][Full Text] [Related]
23. Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G-protein-coupled receptor protease-activated receptor 1. Hamill CE; Caudle WM; Richardson JR; Yuan H; Pennell KD; Greene JG; Miller GW; Traynelis SF Mol Pharmacol; 2007 Sep; 72(3):653-64. PubMed ID: 17596374 [TBL] [Abstract][Full Text] [Related]
25. Resistance to cerebral ischemic injury in UCP2 knockout mice: evidence for a role of UCP2 as a regulator of mitochondrial glutathione levels. de Bilbao F; Arsenijevic D; Vallet P; Hjelle OP; Ottersen OP; Bouras C; Raffin Y; Abou K; Langhans W; Collins S; Plamondon J; Alves-Guerra MC; Haguenauer A; Garcia I; Richard D; Ricquier D; Giannakopoulos P J Neurochem; 2004 Jun; 89(5):1283-92. PubMed ID: 15147521 [TBL] [Abstract][Full Text] [Related]
26. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease. Schmidt N; Ferger B Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221 [TBL] [Abstract][Full Text] [Related]
27. MTH1, an oxidized purine nucleoside triphosphatase, protects the dopamine neurons from oxidative damage in nucleic acids caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Yamaguchi H; Kajitani K; Dan Y; Furuichi M; Ohno M; Sakumi K; Kang D; Nakabeppu Y Cell Death Differ; 2006 Apr; 13(4):551-63. PubMed ID: 16273081 [TBL] [Abstract][Full Text] [Related]
28. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease. Sconce MD; Churchill MJ; Greene RE; Meshul CK Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481 [TBL] [Abstract][Full Text] [Related]
29. Activated microglia affect the nigro-striatal dopamine neurons differently in neonatal and aged mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Sawada H; Hishida R; Hirata Y; Ono K; Suzuki H; Muramatsu S; Nakano I; Nagatsu T; Sawada M J Neurosci Res; 2007 Jun; 85(8):1752-61. PubMed ID: 17469135 [TBL] [Abstract][Full Text] [Related]
30. Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo. Kim HW; Choi WS; Sorscher N; Park HJ; Tronche F; Palmiter RD; Xia Z Neurobiol Aging; 2015 Sep; 36(9):2617-27. PubMed ID: 26070241 [TBL] [Abstract][Full Text] [Related]
31. Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease. Han J; Cheng FC; Yang Z; Dryhurst G J Neurochem; 1999 Oct; 73(4):1683-95. PubMed ID: 10501216 [TBL] [Abstract][Full Text] [Related]
32. Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Schlüter OM; Fornai F; Alessandrí MG; Takamori S; Geppert M; Jahn R; Südhof TC Neuroscience; 2003; 118(4):985-1002. PubMed ID: 12732244 [TBL] [Abstract][Full Text] [Related]
33. Overexpression of TFAM, NRF-1 and myr-AKT protects the MPP(+)-induced mitochondrial dysfunctions in neuronal cells. Piao Y; Kim HG; Oh MS; Pak YK Biochim Biophys Acta; 2012 May; 1820(5):577-85. PubMed ID: 21856379 [TBL] [Abstract][Full Text] [Related]
35. Estrogen receptors and gonadal steroids in vulnerability and protection of dopamine neurons in a mouse model of Parkinson's disease. Al-Sweidi S; Morissette M; Bourque M; Di Paolo T Neuropharmacology; 2011 Sep; 61(4):583-91. PubMed ID: 21586296 [TBL] [Abstract][Full Text] [Related]
36. Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease. Leng A; Mura A; Feldon J; Ferger B Neurosci Lett; 2005 Feb; 375(2):107-11. PubMed ID: 15670651 [TBL] [Abstract][Full Text] [Related]
37. Guanosine diphosphate exerts a lower effect on superoxide release from mitochondrial matrix in the brains of uncoupling protein-2 knockout mice: new evidence for a putative novel function of uncoupling proteins as superoxide anion transporters. Suski JM; Schönfeld P; Bonora M; Shabalina I; Pinton P; Więckowski MR Biochem Biophys Res Commun; 2012 Nov; 428(2):234-8. PubMed ID: 23068098 [TBL] [Abstract][Full Text] [Related]
38. Estrogen reduces BDNF level, but maintains dopaminergic cell density in the striatum of MPTP mouse model. Tripanichkul W; Gerdprasert O; Jaroensuppaperch EO Int J Neurosci; 2010 Jul; 120(7):489-95. PubMed ID: 20583901 [TBL] [Abstract][Full Text] [Related]
39. Mitochondrial hyperpolarization in pulmonary vascular remodeling. Mitochondrial uncoupling protein deficiency as disease model. Pak O; Sommer N; Hoeres T; Bakr A; Waisbrod S; Sydykov A; Haag D; Esfandiary A; Kojonazarov B; Veit F; Fuchs B; Weisel FC; Hecker M; Schermuly RT; Grimminger F; Ghofrani HA; Seeger W; Weissmann N Am J Respir Cell Mol Biol; 2013 Sep; 49(3):358-67. PubMed ID: 23590303 [TBL] [Abstract][Full Text] [Related]
40. Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss. Alam G; Edler M; Burchfield S; Richardson JR Neurotoxicology; 2017 May; 60():99-106. PubMed ID: 28377118 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]